FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022101062> ?p ?o ?g. }

• W2022101062 endingPage "747" @default.
• W2022101062 startingPage "739" @default.
• W2022101062 abstract ": To determine the prophylactic properties of amifostine against acute and late toxicities from radiochemotherapy in patients with head-and-neck cancer. : Fifty patients were randomized to receive conventional radiotherapy (RT) (2-Gy fractions, 5 days weekly, to a total of 60–74 Gy, depending on the tumor localization and TNM classification) and carboplatin (90 mg/m2 infusion once per week before RT). Amifostine (300 mg/m2) was administered in the study group only 15–30 min before RT for 6–7.5 weeks. The primary study end point was the grading of acute and late nonhematologic toxicities (mucositis, dysphagia, xerostomia) induced by radiochemotherapy. Secondary end points included treatment duration, hematologic toxicity, and clinical outcome. : The treatment duration was significantly shorter in the amifostine-treated group (p = 0.013), because treatment interruptions were more frequent in the control group. Acute toxicities (mucositis and dysphagia) were less severe in the amifostine-treated group. By Week 3, all in the control group experienced Grade 2 mucositis compared with only 9% in the amifostine-treated group (p <0.0001). By Week 5, 52.2% of the patients in the control group experienced Grade 4 mucositis compared with 4.5% in the amifostine-treated group (p = 0.0006). Similar results were obtained for dysphagia. At 3 months of follow-up, only 27% of patients in the study group experienced Grade 2 xerostomia compared with 73.9% in the control group (p = 0.0001). Eighteen months after cessation of therapy, the proportion of patients with Grade 2 xerostomia was 4.5% vs. 30.4% for each respective treatment group (p = 0.047). Cytoprotection with amifostine did not affect treatment outcome, with 90.9% complete responses in the amifostine-treated group compared with 78.3% in the control group (p = 0.414). : Amifostine was effective in reducing mucositis and dysphagia resulting from radiochemotherapy in patients with head-and-neck cancer. Furthermore, amifostine reduced the severity of late xerostomia, a side effect of RT with long-lasting consequences. Amifostine treatment did not affect the clinical outcome." @default.
• W2022101062 created "2016-06-24" @default.
• W2022101062 creator A5040999183 @default.
• W2022101062 creator A5051649373 @default.
• W2022101062 creator A5059166933 @default.
• W2022101062 creator A5063094755 @default.
• W2022101062 creator A5070298773 @default.
• W2022101062 date "2002-03-01" @default.
• W2022101062 modified "2023-10-11" @default.
• W2022101062 title "Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer" @default.
• W2022101062 cites W1759456481 @default.
• W2022101062 cites W1895775305 @default.
• W2022101062 cites W1983787272 @default.
• W2022101062 cites W2002992903 @default.
• W2022101062 cites W2007829215 @default.
• W2022101062 cites W2026349090 @default.
• W2022101062 cites W2029767004 @default.
• W2022101062 cites W2032795071 @default.
• W2022101062 cites W2053469511 @default.
• W2022101062 cites W2065657803 @default.
• W2022101062 cites W2068571499 @default.
• W2022101062 cites W2072198722 @default.
• W2022101062 cites W2072896035 @default.
• W2022101062 cites W2077881950 @default.
• W2022101062 cites W2078591171 @default.
• W2022101062 cites W2078771003 @default.
• W2022101062 cites W2085409346 @default.
• W2022101062 cites W2085510134 @default.
• W2022101062 cites W2087977674 @default.
• W2022101062 cites W2104854477 @default.
• W2022101062 cites W2105150213 @default.
• W2022101062 cites W2106257072 @default.
• W2022101062 cites W2113244431 @default.
• W2022101062 cites W2115794884 @default.
• W2022101062 cites W2118170166 @default.
• W2022101062 cites W2125919881 @default.
• W2022101062 cites W2133555954 @default.
• W2022101062 cites W2147384904 @default.
• W2022101062 cites W2155019837 @default.
• W2022101062 cites W2157885764 @default.
• W2022101062 cites W2164157162 @default.
• W2022101062 cites W2331395194 @default.
• W2022101062 doi "https://doi.org/10.1016/s0360-3016(01)02683-9" @default.
• W2022101062 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11849797" @default.
• W2022101062 hasPublicationYear "2002" @default.
• W2022101062 type Work @default.
• W2022101062 sameAs 2022101062 @default.
• W2022101062 citedByCount "213" @default.
• W2022101062 countsByYear W20221010622012 @default.
• W2022101062 countsByYear W20221010622013 @default.
• W2022101062 countsByYear W20221010622014 @default.
• W2022101062 countsByYear W20221010622015 @default.
• W2022101062 countsByYear W20221010622016 @default.
• W2022101062 countsByYear W20221010622017 @default.
• W2022101062 countsByYear W20221010622018 @default.
• W2022101062 countsByYear W20221010622019 @default.
• W2022101062 countsByYear W20221010622020 @default.
• W2022101062 countsByYear W20221010622021 @default.
• W2022101062 countsByYear W20221010622022 @default.
• W2022101062 countsByYear W20221010622023 @default.
• W2022101062 crossrefType "journal-article" @default.
• W2022101062 hasAuthorship W2022101062A5040999183 @default.
• W2022101062 hasAuthorship W2022101062A5051649373 @default.
• W2022101062 hasAuthorship W2022101062A5059166933 @default.
• W2022101062 hasAuthorship W2022101062A5063094755 @default.
• W2022101062 hasAuthorship W2022101062A5070298773 @default.
• W2022101062 hasConcept C126322002 @default.
• W2022101062 hasConcept C141071460 @default.
• W2022101062 hasConcept C2776530083 @default.
• W2022101062 hasConcept C2776694085 @default.
• W2022101062 hasConcept C2778239845 @default.
• W2022101062 hasConcept C2778496288 @default.
• W2022101062 hasConcept C2779387952 @default.
• W2022101062 hasConcept C2780596822 @default.
• W2022101062 hasConcept C2781451048 @default.
• W2022101062 hasConcept C509974204 @default.
• W2022101062 hasConcept C71924100 @default.
• W2022101062 hasConcept C90924648 @default.
• W2022101062 hasConceptScore W2022101062C126322002 @default.
• W2022101062 hasConceptScore W2022101062C141071460 @default.
• W2022101062 hasConceptScore W2022101062C2776530083 @default.
• W2022101062 hasConceptScore W2022101062C2776694085 @default.
• W2022101062 hasConceptScore W2022101062C2778239845 @default.
• W2022101062 hasConceptScore W2022101062C2778496288 @default.
• W2022101062 hasConceptScore W2022101062C2779387952 @default.
• W2022101062 hasConceptScore W2022101062C2780596822 @default.
• W2022101062 hasConceptScore W2022101062C2781451048 @default.
• W2022101062 hasConceptScore W2022101062C509974204 @default.
• W2022101062 hasConceptScore W2022101062C71924100 @default.
• W2022101062 hasConceptScore W2022101062C90924648 @default.
• W2022101062 hasIssue "3" @default.
• W2022101062 hasLocation W20221010621 @default.
• W2022101062 hasLocation W20221010622 @default.
• W2022101062 hasOpenAccess W2022101062 @default.
• W2022101062 hasPrimaryLocation W20221010621 @default.
• W2022101062 hasRelatedWork W1572341506 @default.
• W2022101062 hasRelatedWork W2072198722 @default.
• W2022101062 hasRelatedWork W2082537826 @default.

• next